These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8131661)

  • 1. Non-excretory myeloma with diffuse osteolytic lesions caused by tumor necrosis factor: report of a case.
    Hung KY; Wang CR; Chen YC; Chuang CY
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1993 Feb; 26(1):51-5. PubMed ID: 8131661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A wrong move in an amateur football player reveals a light chain myeloma].
    Peyneau M; Nassiri S; Myara A; Ohana S; Laplanche S
    Ann Biol Clin (Paris); 2016; 74(1):103-5. PubMed ID: 26878614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report. Non-secretory multiple myeloma presenting with diffuse sclerosis of affected bones interspersed with osteolytic lesions.
    Prasad R; Yadav RR; Singh A; Mathur SP; Mangal Y; Singh M
    Br J Radiol; 2009 Feb; 82(974):e29-31. PubMed ID: 19168686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unusual evolution of Waldenström's macroglobulinemia into osteolytic myeloma.
    Jondeau K; Alterescu R; Franc B; Davi F; Massé JM; Boukour S; Le Parc JM; Cramer EM
    Eur J Haematol; 2006 Jul; 77(1):74-9. PubMed ID: 16827885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
    Dogaru M; Lazăr V; Coriu D
    Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
    Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
    Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma invasion of the central nervous system.
    Marjanović S; Mijusković Z; Stamatović D; Madjaru L; Ralić T; Trimcev J; Stojanović J; Radović V
    Vojnosanit Pregl; 2012 Feb; 69(2):209-13. PubMed ID: 22500379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
    Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
    Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [2 cases of multiple myeloma with osteosclerosis].
    Felder M; Keiser G; Wirth W
    Schweiz Med Wochenschr; 1979 Nov; 109(44):1713-9. PubMed ID: 524105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgG-kappa type multiple myeloma in alcoholic cirrhosis--a case report.
    Matsumoto K; Dohmen K; Yamano Y; Omori F; Nagano M; Tajimi T; Iwata Y; Ishibashi H
    Fukuoka Igaku Zasshi; 1991 Jun; 82(6):391-7. PubMed ID: 1909287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-secretory multiple myeloma with diagnostic challenges.
    Hamidah NH; Azma RZ; Ezalia E; Das S; Umar NA; Swaminathan M; Mohamed Z; Abdul Wahid SF
    Clin Ter; 2010; 161(5):445-8. PubMed ID: 20949241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma: diagnosis and treatment.
    Nau KC; Lewis WD
    Am Fam Physician; 2008 Oct; 78(7):853-9. PubMed ID: 18841734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Unusual presentation of plasma cell myeloma].
    Bürgesser MV; Basquiera AL; Diller A
    Medicina (B Aires); 2012; 72(3):251-4. PubMed ID: 22763165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biclonal gammopathy in multiple myeloma: a case report.
    Bakta IM; Sutarka IN
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():544-8. PubMed ID: 10895208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced lytic lesion is a poor mobilization factor in peripheral blood stem cell collection in patients with multiple myeloma.
    Jung SH; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
    J Clin Apher; 2014 Dec; 29(6):305-10. PubMed ID: 24764270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
    Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
    Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
    Pilarski LM; Belch AR
    Clin Cancer Res; 2002 Oct; 8(10):3198-204. PubMed ID: 12374689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Rare Variant of Multiple Myeloma; Non-Secretory Myeloma with diffuse osteolytic lesions.
    Sultan S; Irfan SM
    Gulf J Oncolog; 2015 May; 1(18):28-31. PubMed ID: 26003102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple myeloma arising from monoclonal gammopathy of undetermined significance in a patient with Gaucher's disease.
    Brady K; Corash L; Bhargava V
    Arch Pathol Lab Med; 1997 Oct; 121(10):1108-11. PubMed ID: 9341594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
    Bianchi G; Richardson PG; Anderson KC
    J Clin Oncol; 2014 Jul; 32(20):2125-32. PubMed ID: 24888801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.